Clinical outcomes of standard triple therapy plus probiotics or concomitant therapy for Helicobacter pylori infection

Jae Hyun Jung, In Kuk Cho, Chang Hee Lee, Gwan Gyu Song, Ji Hyun Lim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: The efficacy of standard triple therapy (STT) in treating Helicobacter pylori infection has decreased. Many investigators have attempted to increase the eradication rate. We investigated the outcomes of concomitant therapy (CT) and STT combined with probiotics (STP) as a first-line treatment for H. pylori infection. Methods: We reviewed the medical records of 361 patients who received either STP (n=286) or CT (n=75). The STP group received STT combined with a probiotic preparation for 1 week. The CT group received STT and metronidazole for 1 week. Results: The intention-to-treat and per-protocol eradication rates were 83.6% (95% confidence interval [CI], 79.0 to 87.7) and 87.1% (95% CI, 81.2 to 89.7) in the STP group and 86.7% (95% CI, 78.7 to 93.3) and 91.4% (95% CI, 83.6 to 97.1) in the CT group (p=0.512 and p=0.324), respectively. The frequency of adverse effects was higher in the CT group (28.2%) than in the STP group (12.8%) (p=0.002). Conclusions: STP and CT are encouragingly efficacious as first-line treatments for H. pylori infection. Therefore, adding probiotics to STT may be a feasible option to avoid side effects. (Gut Liver 2018;12:165-172).

Original languageEnglish
Pages (from-to)165-172
Number of pages8
JournalGut and Liver
Volume12
Issue number2
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Probiotics
Helicobacter Infections
Helicobacter pylori
Group Psychotherapy
Confidence Intervals
Therapeutics
Metronidazole
Medical Records
Research Personnel
Liver

Keywords

  • Helicobacter pylori
  • Metronidazole
  • Probiotics

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Clinical outcomes of standard triple therapy plus probiotics or concomitant therapy for Helicobacter pylori infection. / Jung, Jae Hyun; Cho, In Kuk; Lee, Chang Hee; Song, Gwan Gyu; Lim, Ji Hyun.

In: Gut and Liver, Vol. 12, No. 2, 01.03.2018, p. 165-172.

Research output: Contribution to journalArticle

Jung, Jae Hyun ; Cho, In Kuk ; Lee, Chang Hee ; Song, Gwan Gyu ; Lim, Ji Hyun. / Clinical outcomes of standard triple therapy plus probiotics or concomitant therapy for Helicobacter pylori infection. In: Gut and Liver. 2018 ; Vol. 12, No. 2. pp. 165-172.
@article{065009ca62dc43b69fb115a6fecf9ba3,
title = "Clinical outcomes of standard triple therapy plus probiotics or concomitant therapy for Helicobacter pylori infection",
abstract = "Background/Aims: The efficacy of standard triple therapy (STT) in treating Helicobacter pylori infection has decreased. Many investigators have attempted to increase the eradication rate. We investigated the outcomes of concomitant therapy (CT) and STT combined with probiotics (STP) as a first-line treatment for H. pylori infection. Methods: We reviewed the medical records of 361 patients who received either STP (n=286) or CT (n=75). The STP group received STT combined with a probiotic preparation for 1 week. The CT group received STT and metronidazole for 1 week. Results: The intention-to-treat and per-protocol eradication rates were 83.6{\%} (95{\%} confidence interval [CI], 79.0 to 87.7) and 87.1{\%} (95{\%} CI, 81.2 to 89.7) in the STP group and 86.7{\%} (95{\%} CI, 78.7 to 93.3) and 91.4{\%} (95{\%} CI, 83.6 to 97.1) in the CT group (p=0.512 and p=0.324), respectively. The frequency of adverse effects was higher in the CT group (28.2{\%}) than in the STP group (12.8{\%}) (p=0.002). Conclusions: STP and CT are encouragingly efficacious as first-line treatments for H. pylori infection. Therefore, adding probiotics to STT may be a feasible option to avoid side effects. (Gut Liver 2018;12:165-172).",
keywords = "Helicobacter pylori, Metronidazole, Probiotics",
author = "Jung, {Jae Hyun} and Cho, {In Kuk} and Lee, {Chang Hee} and Song, {Gwan Gyu} and Lim, {Ji Hyun}",
year = "2018",
month = "3",
day = "1",
doi = "10.5009/gnl17177",
language = "English",
volume = "12",
pages = "165--172",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "2",

}

TY - JOUR

T1 - Clinical outcomes of standard triple therapy plus probiotics or concomitant therapy for Helicobacter pylori infection

AU - Jung, Jae Hyun

AU - Cho, In Kuk

AU - Lee, Chang Hee

AU - Song, Gwan Gyu

AU - Lim, Ji Hyun

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background/Aims: The efficacy of standard triple therapy (STT) in treating Helicobacter pylori infection has decreased. Many investigators have attempted to increase the eradication rate. We investigated the outcomes of concomitant therapy (CT) and STT combined with probiotics (STP) as a first-line treatment for H. pylori infection. Methods: We reviewed the medical records of 361 patients who received either STP (n=286) or CT (n=75). The STP group received STT combined with a probiotic preparation for 1 week. The CT group received STT and metronidazole for 1 week. Results: The intention-to-treat and per-protocol eradication rates were 83.6% (95% confidence interval [CI], 79.0 to 87.7) and 87.1% (95% CI, 81.2 to 89.7) in the STP group and 86.7% (95% CI, 78.7 to 93.3) and 91.4% (95% CI, 83.6 to 97.1) in the CT group (p=0.512 and p=0.324), respectively. The frequency of adverse effects was higher in the CT group (28.2%) than in the STP group (12.8%) (p=0.002). Conclusions: STP and CT are encouragingly efficacious as first-line treatments for H. pylori infection. Therefore, adding probiotics to STT may be a feasible option to avoid side effects. (Gut Liver 2018;12:165-172).

AB - Background/Aims: The efficacy of standard triple therapy (STT) in treating Helicobacter pylori infection has decreased. Many investigators have attempted to increase the eradication rate. We investigated the outcomes of concomitant therapy (CT) and STT combined with probiotics (STP) as a first-line treatment for H. pylori infection. Methods: We reviewed the medical records of 361 patients who received either STP (n=286) or CT (n=75). The STP group received STT combined with a probiotic preparation for 1 week. The CT group received STT and metronidazole for 1 week. Results: The intention-to-treat and per-protocol eradication rates were 83.6% (95% confidence interval [CI], 79.0 to 87.7) and 87.1% (95% CI, 81.2 to 89.7) in the STP group and 86.7% (95% CI, 78.7 to 93.3) and 91.4% (95% CI, 83.6 to 97.1) in the CT group (p=0.512 and p=0.324), respectively. The frequency of adverse effects was higher in the CT group (28.2%) than in the STP group (12.8%) (p=0.002). Conclusions: STP and CT are encouragingly efficacious as first-line treatments for H. pylori infection. Therefore, adding probiotics to STT may be a feasible option to avoid side effects. (Gut Liver 2018;12:165-172).

KW - Helicobacter pylori

KW - Metronidazole

KW - Probiotics

UR - http://www.scopus.com/inward/record.url?scp=85045952995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045952995&partnerID=8YFLogxK

U2 - 10.5009/gnl17177

DO - 10.5009/gnl17177

M3 - Article

VL - 12

SP - 165

EP - 172

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 2

ER -